ResultsIQ › Latest results › Biocon Limited
Biocon Limited Q2 FY27 earnings call summary
NSE: BIOCON · BSE: 532523
Earnings call of 4 Nov 2026, summarised by AI from the filing.
Biocon Q2 FY27 EBITDA ₹865 cr on 2% revenue growth, with H2 FY27 guided stronger than H1 and about 5% of revenue deferred to Q3.
Key takeaways
- Pertuzumab Genentech settlement and $400 million Brazil PDP contract open launches from Q4FY27, EU early 2027 and U.S. Q3 calendar 2028.
- Competition Yesafili faces expected competition and Part B biosimilar pricing can take away margins.
Biocon Limited Q2 FY27 results
As filed: Revenue ₹4,389 cr (+2% year on year), EBITDA ₹831 cr (0% year on year), PAT ₹56.7 cr (−66% year on year), EBITDA margin 18.9% (−50 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹4,336 cr (+10% year on year), EBITDA ₹847 cr (+13% year on year), PAT ₹137 cr (+45% year on year), EBITDA margin 19.5% (+54 bps). Score 48 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit before exceptional items growth was in line with it. EBITDA margin rose 54 bps year on year. Other income 43% of PBT. Tax rate -7%. Revenue fell 4% from last quarter. Share price after the results: −6.5% in 30 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹4,517 cr (+2% year on year), EBITDA ₹1,020 cr (−5% year on year), PAT ₹199 cr (−30% year on year), EBITDA margin 22.6% (−182 bps). Score 32 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin fell 182 bps year on year. Consolidated profit -57% but standalone +143%. Share price after the results: +7.9% in 29 days (Nifty 500: −3.2%).
- Q3 FY26: Revenue ₹4,173 cr (+9% year on year), EBITDA ₹834 cr (+11% year on year), PAT −₹51.8 cr (+63% year on year), EBITDA margin 20.0% (+32 bps). Score 53 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 32 bps year on year. Share price after the results: +2.3% in 29 days (Nifty 500: −9.6%).
- Q2 FY26: Revenue ₹4,296 cr (+20% year on year), EBITDA ₹835 cr (+22% year on year), PAT ₹133 cr (+300% year on year), EBITDA margin 19.4% (+36 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well above it. EBITDA margin rose 36 bps year on year. Other income 54% of PBT. Share price after the results: −0.9% in 30 days (Nifty 500: −0.6%).
- Q1 FY26: Revenue ₹3,942 cr (+15% year on year), EBITDA ₹749 cr (+21% year on year), PAT ₹89.0 cr (−90% year on year), EBITDA margin 19.0% (+94 bps). Score 46 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was below it. EBITDA margin rose 94 bps year on year. Other income 82% of PBT. Tax rate 8%. Revenue fell 11% from last quarter. Share price after the results: −0.1% in 29 days (Nifty 500: +0.6%).
- Q4 FY25: Revenue ₹4,417 cr (+13% year on year), EBITDA ₹1,078 cr (+18% year on year), PAT ₹459 cr (+106% year on year), EBITDA margin 24.4% (+102 bps). Score 61 of 100, In line with trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 102 bps year on year. Tax rate 6%. Share price after the results: −1.4% in 29 days (Nifty 500: +6.1%).
- Q3 FY25: Revenue ₹3,821 cr (−3% year on year), EBITDA ₹751 cr (−19% year on year), PAT ₹81.0 cr (−83% year on year), EBITDA margin 19.7% (−379 bps). Score 20 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin fell 379 bps year on year. Tax rate 48%. Consolidated profit -89% but standalone +2333%.
Past price moves after results do not indicate future moves. Not a recommendation.
Biocon Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (4 Nov 2026), Results deck (4 Nov 2026)
- Q1 FY27: Earnings call (6 Aug 2026), Results deck (6 Aug 2026)
- Q4 FY26: Earnings call (8 May 2026), Results deck (8 May 2026)
- Q3 FY26: Earnings call (13 Feb 2026), Results deck (13 Feb 2026)
- Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
- Q1 FY26: Earnings call (8 Aug 2025), Results deck (8 Aug 2025)
- Q4 FY25: Earnings call (9 May 2025), Results deck (9 May 2025)
- Other events: Strategy deck (1 Jun 2026), Strategy deck (25 Feb 2026), Strategy deck (9 Dec 2025), Strategy deck (6 Dec 2025), Strategy deck (12 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.